<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148534</url>
  </required_header>
  <id_info>
    <org_study_id>D-4-2019</org_study_id>
    <nct_id>NCT04148534</nct_id>
  </id_info>
  <brief_title>Compare the Operating Condition of Two Levels of Muscle Relaxation on Facial Nerve MEP Monitoring in CPA Surgery</brief_title>
  <official_title>Intraoperative Motor Evoked Potential Monitoring of Facial Nerve in Patients Undergoing Cerbellopontine Angle Tumer Resection Using Partial Versus no Neuromuscular Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muhammad Magdy Gaber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      compare the operating condition of two different levels of muscle relaxation on facial nerve
      monitoring using transcranial motor evocked potential in CPA surgery .

        -  To Estimate End to start facial nerve MEP amplitude ratio

        -  To determine the effect of neuromuscular relaxant degrees on recovery and

        -  Assessment of propofol doses needed for enhancement of early recovery and ambulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 Patients aged from 18-60 years old undergoing Cerebellopontine angle surgery. Patients
      will be one of two groups: Both Induction will be accomplished with fentanyl, propofol ,
      rocronium infusion will be given randomly to one of the groups.

      Depth of anaesthesia, neurotransmitter monitoring and facial nerve neurophysiological
      monitoring will be done.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1- End to start facial nerve MEP amplitude ratio.</measure>
    <time_frame>6 to 8 month</time_frame>
    <description>TCMEP recording will begin (1) prior to skin incision as baseline amplitude before muscle relaxant be taken for intubation (2) at Dural closure and end \start amplitude ratio will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2- Total volume of propofol infused</measure>
    <time_frame>6 to 8 month</time_frame>
    <description>Calculate dose consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebellopontine Angle Tumor</condition>
  <arm_group>
    <arm_group_label>rocronium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Facial motor evoked potential monitoring in patient who will receive Rocronium as muscle relaxant, patients will receive rocuronium infusion by (5mcg/kg/min) , twenty minutes after induction. maintain partial NMB T2\TC 0.5 or TOF count 2 and targeting BIS = (40-60)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No rocronium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Facial motor evoked potential monitoring in patient who will not receive muscle relaxant, targeting BIS = 25-35 after ending of monitoring of neurophysiology propofol dose will be dropped to 4-6 mg\kg\hr. targeting Bispecteral index 40- 60.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rocronium</intervention_name>
    <description>compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery</description>
    <arm_group_label>No rocronium</arm_group_label>
    <arm_group_label>rocronium</arm_group_label>
    <other_name>Facial nerve MEP monitoring</other_name>
    <other_name>Nerve stimulator for train of four assessment</other_name>
    <other_name>BIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age between &gt;18 and&lt;60.

          -  Patients scheduled for neurosurgical CPA surgeries

          -  Ability to sign the consent

          -  ASA classification I, II

        Exclusion Criteria:

          -  ASA &gt; II

          -  Hemodynamically unstable

          -  Disease affecting neuromuscular transmission (myasthenia gravies ...etc.)

          -  GCS &lt; 15.

          -  Any cardiac patient (ischemic heart disease - cardiomyopathy...etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cairo university</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo university faculty of medicine research ethical committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo university medical school</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Muhammad Magdy Gaber</investigator_full_name>
    <investigator_title>Assisstant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT04148534/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

